Area of research
Surgery · Finance
Research interest
Research focused on Hazard ratio and Helicobacter pylori, with related work in Gastroenterology, Hepatic stellate cell, Furazolidone. Notable publications include 'Long-term follow-up of Helicobacter pylori reinfection and its risk factors after initial eradication: a large-scale multicentre, prospective open cohort, observational study', 'On‐treatment changes of liver stiffness at week 26 could predict 2‐year clinical outcomes in HBV ‐related compensated cirrhosis', and 'Antioxidant axis Nrf2-keap1-ARE in inhibition of alcoholic liver fibrosis by IL-22'.
Diagnosis and treatment of <i>Helicobacter pylori</i> infection by physicians in China: A nationwide cross‐sectional study
Efficacy of keverprazan for duodenal ulcer: A phase II randomized, double‐blind, parallel‐controlled trial
Mucosal Healing Effectiveness and Safety of Anaprazole, a Novel PPI, vs. Rabeprazole in Patients With Duodenal Ulcers: A Randomized Double-Blinded Multicenter Phase II Clinical Trial
Long-term follow-up of <i>Helicobacter pylori</i> reinfection and its risk factors after initial eradication: a large-scale multicentre, prospective open cohort, observational study
Furazolidone‐containing triple and quadruple eradication therapy for initial treatment for <i>Helicobacter pylori</i> infection: A multicenter randomized controlled trial in China
On‐treatment changes of liver stiffness at week 26 could predict 2‐year clinical outcomes in <scp>HBV</scp>‐related compensated cirrhosis
Antioxidant axis Nrf2-keap1-ARE in inhibition of alcoholic liver fibrosis by IL-22
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Surgery · Finance →